Discovery of a Hydroxylamine-Based Brain-Penetrant EGFR Inhibitor for Metastatic Non-Small-Cell Lung Cancer

Area of Science:

• Medicinal Chemistry
• Oncology
• Pharmacology

Background:

• Brain metastases are a major challenge in lung cancer treatment.
• Existing therapies are limited by the blood-brain barrier (BBB) and drug efflux transporters.
• Epidermal growth factor receptor (EGFR) mutations drive non-small-cell lung cancer (NSCLC) and resistance to targeted therapies.

Purpose of the Study:

• To discover and characterize a novel, brain-penetrant EGFR inhibitor for treating lung cancer brain metastases.
• To evaluate the efficacy of the novel inhibitor in preclinical models of EGFR-mutant NSCLC.
• To explore the utility of trisubstituted hydroxylamine moieties in drug design.

Main Methods:

• Discovery and synthesis of a selective, orally bioavailable EGFR inhibitor (compound 9).
• Assessment of compound 9's activity in osimertinib-resistant cell lines with specific EGFR mutations (L858R/C797S, exon19del/C797S).
• Evaluation of compound 9's in vivo efficacy in an intracranial patient-derived xenograft (PDX) murine model.

Main Results:

• Compound 9 demonstrated high brain penetration and potent activity against EGFR-mutant, osimertinib-resistant NSCLC cell lines.
• In vivo studies showed that compound 9 induced tumor regression in an intracranial PDX model.
• The trisubstituted hydroxylamine moiety was successfully incorporated without significant toxicity or molecular weight increase.

Conclusions:

• Compound 9 is a promising lead candidate for treating EGFR-mutant NSCLC, including brain metastases.
• This study validates the use of trisubstituted hydroxylamines in developing potent and brain-penetrant drug molecules.
• Targeting brain metastases in NSCLC can be achieved with novel, BBB-penetrant EGFR inhibitors.